Researchers recently completed a study identifying the incidence of insulin resistance in HIV-patients who exhibit signs of lipodystrophy. The authors noted two significant metabolic changes occurring in those patients, including significant insulin resistance and hyperlipidemia linked to fat redistribution. The characteristic bunching of metabolic abnormalities, as exhibited by fasting hyperinsulinemia in relationship to normal fasting glucose levels, results in a high insulin resistance condition and may also place HIV-infected lipodystrophy patients at a higher risk for cardiovascular disease (CVD). Another significant factor for CVD risk is the weight gain associated with HIV-related lipodystrophy and insulin resistance. There are insulin-sensitizing drug compounds currently being used to combat the metabolic changes brought on by the condition, but further clinical trials are recommended to determine the long-term effects of the treatment. The researchers feel that until more is understood about the condition, clinicians should recommend a treatment program based on modified diet, exercise, and weight management for patients with HIV-associated lipodystrophy.

Other CDC News for March 12, 2001

South Africa May Cite Crisis to Lower Cost of AIDS Drugs Yale Pressed to Help Cut Drug Costs in Africa Merck & Co. Advertisement Behind Cipla's Offer of Cheap AIDS Drugs: Potent Mix of Motives	Africa: Ivory Coast Makes Deal for Cheaper HIV Drugs AIDS Permeates Uganda Politics Too Public Health Spending Up in City, Town of Burlington; Sexually Transmitted Disease Cases Jumped 50 Percent From 1999 Russians Admit to 300,000 HIV Cases
Insulin Resistance in HIV Lipodystrophy Syndrome